Bundibugyo Ebola Resurgence Reveals Unlinked Patterns of Surveillance Failure and Vaccine Equity Gaps Across Outbreaks

The NYT report frames Bundibugyo as a novel threat driving a fresh vaccine scramble, yet it underplays how this strain's expansion mirrors the 2014 Zaire and 2018-2020 outbreaks in delayed detection and inequitable countermeasure access. Observational data from the two prior Bundibugyo events (Uganda 2007, n=116 cases; DRC 2012, n=36) showed case-fatality rates of 25-34 percent with no RCTs conducted, while the larger 2014-2016 epidemic prompted the rVSV-ZEBOV RCT (Ebola ça Suffit trial, 7,651 participants, ring-vaccination design) that demonstrated 100 percent efficacy in the immediate ring but faced rollout conflicts from pharma partnerships. Current Bundibugyo modeling draws on these same weak observational baselines without integrating One Health surveillance, allowing rapid spread before mRNA or viral-vector candidates advance. This pattern of re-emergence every 4-6 years, unconnected in policy, stems from underfunded regional labs rather than inherent viral novelty, a gap the original coverage overlooks.